award night, page-73

For sure Goldenchook.

Hottod, I see that also. Its too early to start thinking about revenues but its easy to see how low 300m is when you compare the patch to OxyContin (OP). OP has about 15% of the prescription market (5.6m of approx 28m) and annual revenues of 3.5b. If the patch enters the market at the same price point and captures 5% of the prescription market revenues will be 1b. Any future deal must reflect this sort of opportunity.

Also, the way i see it, the FDA decision on Zohydro in March will give some indication to how the FDA intends to make use of the Stop Tampering of Prescription Pills (STOPP) Act. It would be easier for POH to compete in an open market where OC and Opana face generic competition. Im tipping Zohydro is approved but given a date by which it must reformulate its drug to include a tamper deterrent. That would be the better outcome for POH i think.

Thanks Makattack. Thats what i would expect (hope). They key thing is they have the money to complete the PIII trial and that gives them more leverage at the negotiation table.

Heres a bit of related news also...
http://www.bloomberg.com/news/2012-12-18/opioid-painkillers-to-receive-closer-scrutiny-by-u-s-regulators.html